SPOTLIGHT -
EP. 1: ITP Pathogenesis, Presentation, and Diagnostic Workup
EP. 2: ITP Treatment Selection Criteria and Treatment Goals
EP. 3: ITP Patient Management and Important Treatment Factors
EP. 4: First-Line Therapy Options for Patients with ITP
EP. 5: Steroid Combination Therapy & New ASH Guidelines
EP. 6: Second-Line Treatment Options for Patients with ITP
EP. 7: Fostamatinib as Second-Line ITP Therapy
EP. 8: Romiplostim Classification and Mechanism of Action
EP. 9: TPO Receptor Agonist Selection and Patient Adherence
EP. 10: TPO Duration of Response and Toxicity
EP. 11: Rituximab and Salvage Therapies for Patients With ITP
EP. 12: The Future of ITP Treatment
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
